SARSCoV2

LSU Health New Orleans receives $2.38 million in funding to sequence SARS-CoV-2 variants

LSU Health New Orleans receives $2.38 million in funding to sequence SARS-CoV-2 variants

LSU Health New Orleans has been awarded $2.38 million in funding to lead partnerships to sequence SARS-CoV-2 variants. The funding is from a contract with the Louisiana Department of Health (LDH)) and a National Institute of General Medical Sciences supplement to the LACaTS (Louisiana Clinical & Translational Science Center) grant. Lucio Miele, MD, PhD, Professor …

LSU Health New Orleans receives $2.38 million in funding to sequence SARS-CoV-2 variants Read More »

Why do we continue to see outbreaks of SARS-CoV-2 in care homes?

Why do we continue to see outbreaks of SARS-CoV-2 in care homes?

The Charité researchers analyzed blood samples from older and younger individuals who had received their vaccinations, testing for the presence of SARS-CoV-2-specific antibodies (including immunoglobulin G, or IgG). Credit: Charité | Victor Corman SARS-CoV-2 outbreaks involving care homes with fully vaccinated residents have been reported across Germany. In order to gain a better understanding of …

Why do we continue to see outbreaks of SARS-CoV-2 in care homes? Read More »

Study: Mutations in emerging variant of concern lineages disrupt genomic sequencing of SARS-CoV-2 clinical specimens. Image Credit: joshimerbin / Shutterstock

Emerging SARS-CoV-2 variants contain mutations that interfere with genomic sequencing

As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began its deadly march across the world at the end of 2019, beginning the coronavirus disease 2019 (COVID-19) pandemic, viral containment has been the primary focus along with the treatment of symptomatic illness. Genomic surveillance has played a starring role in the early identification of emerging …

Emerging SARS-CoV-2 variants contain mutations that interfere with genomic sequencing Read More »

Young infants produce strong immune response to SARS-CoV-2, study finds

Young infants produce strong immune response to SARS-CoV-2, study finds

Credit: Unsplash/CC0 Public Domain Young infants show strong immune responses to SARS-CoV-2, new research has found. In particular, compared with adults, young infants produce relatively high levels of antibodies and immune cells that can specifically protect against COVID-19. The study led by academics and pediatricians at the University of Bristol and Bristol Royal Hospital for …

Young infants produce strong immune response to SARS-CoV-2, study finds Read More »

Study: DNA damage response at telomeres boosts the transcription of SARS-CoV-2 receptor ACE2 during aging. Image Credit: Kateryna Kon / Shutterstock

What makes the elderly more susceptible to SARS-CoV-2 infection?

Why is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 (coronavirus disease 2019), biased towards infecting the aged population? A recently published study by Italian scientists linked aging, DNA damage, telomere shortening, and increased levels of angiotensin-converting enzyme 2 (ACE2) to this relationship. To better understand the modulation of the ACE2 …

What makes the elderly more susceptible to SARS-CoV-2 infection? Read More »

Study: Mitigating airborne transmission of SARS-CoV-2. Image Credit: NIAID

Long-range airborne transmission of SARS-CoV-2

Infectious droplets generated by coughing, sneezing, or just ordinary speech and breathing have generally been categorized based on size between “droplets” and “aerosols,” with aerosols representing the smallest particles that can stay airborne, usually evaporating before reaching the ground. The size at which a droplet becomes an aerosol is not clear-cut, with particle diameters ranging …

Long-range airborne transmission of SARS-CoV-2 Read More »

Study: The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 B.1.351 and other variants of concern in preclinical studies. Image Credit: F8 studio / Shutterstock

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

In many countries, the rapid pace of vaccination against coronavirus disease 2019 (COVID-19) has helped to reduce the number of new cases and hospitalizations remarkably. Simultaneously, however, new strains are emerging that show resistance to antibodies elicited by earlier strains, and/or increased transmissibility. A new study, released on the bioRxiv* preprint server, supports the efficacy …

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern Read More »

Study: Single-dose mRNA vaccine effectiveness against SARS-CoV-2, including P.1 and B.1.1.7 variants: a test-negative design in adults 70 years and older in British Columbia, Canada. Image Credit: Melinda Nagy / Shutterstock

High single-dose efficacy of Pfizer vaccine against SARS-CoV-2 in older adults

In British Columbia (BC), Canada, vaccination against coronavirus disease 2019 (COVID-19) began with the Pfizer/Moderna mRNA (messenger ribonucleic acid) vaccines began with nursing home residents and frontline healthcare workers. New research by scientists in Canada suggests that these are known to have a high protective efficacy of 92-93% after a single dose, but this data …

High single-dose efficacy of Pfizer vaccine against SARS-CoV-2 in older adults Read More »

Study: Possible Human-to-Dog Transmission of SARS-CoV-2, Italy, 2020. Image Credit: NDAB Creativity / Shutterstock

SARS-CoV-2 infection detected in a poodle living with a COVID-19 positive family

The coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first emerged in Wuhan City, China, in December 2019. The virus is thought to have originated in horseshoe bats and jumped to as yet unverified intermediate hosts before spilling over to human hosts – a process known as zoonosis. Now, …

SARS-CoV-2 infection detected in a poodle living with a COVID-19 positive family Read More »

Study reports compound blocks SARS-CoV-2 and protects lung cells

Study reports compound blocks SARS-CoV-2 and protects lung cells

Credit: CC0 Public Domain Research conducted at LSU Health New Orleans Neuroscience Center of Excellence reports that Elovanoids, bioactive chemical messengers made from omega-3 very-long-chain polyunsaturated fatty acids discovered by the Bazan lab in 2017, may block the virus that causes COVID-19 from entering cells and protect the air cells (alveoli) of the lung. Their …

Study reports compound blocks SARS-CoV-2 and protects lung cells Read More »